ChemGenex Pharmaceuticals

About:

ChemGenex Pharmaceuticals Ltd, an integrated biopharmaceutical development company, engages in the discovery and the development of

Website: http://www.chemgenex.com

Top Investors: Alta Partners, GBS Ventures

Description:

ChemGenex Pharmaceuticals Ltd, an integrated biopharmaceutical development company, engages in the discovery and the development of oncology drugs. The company's product candidates include omacetaxine mepesuccinate, an investigational small molecule agent that is in Phase 2/3 clinical trial for the treatment of chronic myelogenous leukemia, and is also in Phase 2 clinical trials for the treatment of acute myelogenous leukemia and myelodysplastic syndrome; and Quinamed, which is in Phase 2 clinical trial for the treatment of hormone refractory prostate cancer. It was formerly known as AGT Biosciences Limited and changed its name to ChemGenex Pharmaceuticals Ltd in June 2004. The company was founded in 1958 and is headquartered in Geelong, Australia.

Total Funding Amount:

21M AUD

Headquarters Location:

Geelong, Victoria, Australia

Founded Date:

1958-01-01

Contact Email:

medinfo(AT)chemgenex.com

Founders:

Number of Employees:

11-50

Last Funding Date:

2007-03-04

IPO Status:

Private

Industries:

© 2025 bioDAO.ai